Clinical Trial: Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07095465) titled 'Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis' on July 24.

Brief Summary: A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Study Start Date: Aug., 2025

Study Type: INTERVENTIONAL

Condition: Lewy Body Dementia Psychosis

Intervention: DRUG: ACP-204

Provided as 1 capsule, to be taken orally once daily

Recruitment Status: NOT_YET_RECRUITING

Sponsor: ACADIA Pharmaceuticals Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....